We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rituximab as a maintenance treatment in patients with pemphigus vulgaris: When is the right time for discontinuation?
- Authors
Aryanian, Zeinab; Balighi, Kamran; Emadi, Seyed Naser; Hatami, Parvaneh
- Abstract
This article discusses the use of rituximab as a maintenance treatment for pemphigus vulgaris, an autoimmune disorder. The article highlights the need for multiple courses of rituximab to keep patients in remission, but also acknowledges the potential complications associated with long-term use of the drug. The authors summarize existing data and experiences of various specialists to provide a practical guide for clinicians. They suggest criteria for discontinuation of treatment, such as negative immunofluorescence results and persistent clinical remission. The article also discusses factors that may predict adverse effects and the potential role of BAFF in repopulation of B cells after rituximab therapy. The authors emphasize the need for further research to determine the optimal timing, duration, and scheduling of rituximab therapy, as well as individualized approaches based on patient characteristics. They also recommend close monitoring of patients for secondary malignancies and suggest oncology consultation for those on long-term rituximab treatment.
- Subjects
PEMPHIGUS vulgaris; DISEASE remission; PEMPHIGUS; TALL-1 (Protein); RITUXIMAB; REGULATORY B cells; CHRONIC myeloid leukemia
- Publication
Journal of Cosmetic Dermatology, 2024, Vol 23, Issue 2, p406
- ISSN
1473-2130
- Publication type
Article
- DOI
10.1111/jocd.16030